Merck gives Vertex exclusive rights to DNA damage inhibitors
Merck has licensed two DNA-dependent protein kinase (DNA-PK) inhibitors back to Vertex Pharmaceuticals.
25th January 2019
Latest news
Circassia pays $32M for rights to AirNOvent
UK group Circassia has announced plans to acquire US and Chinese commercialisation rights to AirNOvent, a novel nitric oxide product, from AIT Therapeutics.
25th January 2019
IND status for MGB Biopharma's CDAD drug
The Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND) for MGB Biopharma’s lead candidate MGB-BP-3, for the treatment of clostridium difficile-associated diarrhoea.
24th January 2019
Antimicrobial resistance "as big a danger to humanity as climate change or warfare"
The UK has launched a five-year action plan and 20-year vision for antimicrobial resistance (AMR).
24th January 2019
Novo Nordisk stockpiling over double usual amount ahead of Brexit
Novo Nordisk says it has planned for all future ‘no-deal’ Brexit contingencies, including doubling UK stock to 16 weeks (around four months of supply), which will be in place by the end of January.
24th January 2019
UK university clinical trials to be monitored
Universities that do not improve on fulfilling their legal obligation to report clinical trials over the next six months could be brought in front of the House of Commons Science and Technology Committee to explain why they have failed to do so.
24th January 2019
RCGP welcomes roll out of NHS App
NHS England has begun to roll out its NHS App to the public, in a move hailed by doctors' leaders as "a significant and constructive step forward in using technology to support patients".
24th January 2019
15-year-old brain cancer patient to receive specialist radiotherapy
A 15-year-old boy with a rare brain tumour is set to begin innovative treatment at the NHS’s new Proton Beam Therapy centre, at The Christie hospital in Manchester.
23rd January 2019
NICE backs digital CBT for mildly depressed children and young people
The National Institute for Health and Care Excellence (NICE) has recommended digital cognitive behavioural therapy for use on the NHS in children and young people with mild depression.
23rd January 2019
Ozempic launched for type II diabetes in the UK
Novo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK.
23rd January 2019
GSK completes Tesaro deal
GlaxoSmithKline has completed its acquisition of Tesaro, the oncology focused biopharmaceutical company.
23rd January 2019
Wren raises £18m to accelerate pipeline
Wren Therapeutics has announced the completion of a Series A financing round totalling £18 million.
23rd January 2019
CR UK streams £60m into tackling global cancer
Cancer Research UK has pledged to tackle global cancer challenges with £60 million funding.
23rd January 2019
Abcam and Loulou Foundation form CDKL5 deficiency disorder partnership
Abcam has announced a research collaboration with the Loulou Foundation to discover new tools to advance research for the development of therapeutics for CDKL5 Deficiency Disorder.
22nd January 2019
Superdrug to offer stricter mental health checks for Botox users
NHS England's medical director has welcomed the introduction of stronger mental health safeguards for Superdrug's new high street botox plan.
22nd January 2019
